New Standards in Advanced-stage Hodgkin Lymphoma: Selecting a Novel Regimen

The management of advanced-stage Hodgkin lymphoma has entered an era defined by immune-based therapy. Nivolumab-AVD has become the preferred frontline regimen, delivering high cure rates with minimal toxicity across age groups. BrECADD remains an effective, fertility-sparing option for select young, fit patients requiring intensification. As outcomes improve, traditional prognostic models and response assessment tools need reassessment. Survivorship principles now guide individualized care that balances efficacy with long-term health. Optimizing survivorship further requires continued efforts to identify both low-risk patients for therapy de-escalation and high-risk patients for alternative approaches.